

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EuroEyes International Eye Clinic Limited

德視佳國際眼科有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1846)

POSITIVE PROFIT ALERT

This announcement is made by EuroEyes International Eye Clinic Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**” and each a “**Director**”) of the Company would like to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2023 (the “**Year**”) and the information currently available to the Board, the Group expects to record: (i) a profit attributable to owners of the Company in the range of approximately HK\$128 million to HK\$135 million, as compared to approximately HK\$89.5 million for the year ended 31 December 2022 (“**Last Year**”); and (ii) the earnings before interest, taxes, depreciation and amortisation (“**EBITDA**”) for the Year in the range of approximately HK\$278 million to HK\$290 million, representing an increase in the range of approximately 30% to 36%, as compared to approximately HK\$214 million for the Last Year.

The Board considers such expected increase in the profit attributable to owners of the Company and EBITDA for the Year as compared to Last Year was principally attributable to (i) the strong economic recovery of the People’s Republic of China and the market conditions following the lifting of the COVID-19 restrictions, which resulted in the increase of the total number of eye surgeries performed by the Group; (ii) the increase in demand for presbyopia surgery, which resulted in an increase in profit contribution; and (iii) the Group’s resilience despite the challenging economic environment as the Group experienced robust growth in the total number of eye surgeries performed in Europe.

The information contained in this announcement is only based on the preliminary assessment of information currently available and the unaudited consolidated management accounts of the Group for the Year by the management of the Company, and is not based on any figures or information audited or reviewed by the Company’s independent auditor and/or audit committee and may be also subject to further adjustment. The Company is still in the process of finalising the final results of the Group for the year ended 31 December 2023.

Further details of the Group's financial results and performance will be disclosed in the Company's results announcement for the year ended 31 December 2023 in compliance with the requirements of the Listing Rules, which shall prevail over the information contained herein. The Board wishes to emphasise that the results of the Group for the year ended 31 December 2023 may be affected by some other factors. As such, the above information is provided for Shareholders' and potential investors' reference only.

Shareholders and potential investors are advised to read carefully the announcement of the annual results of the Group for the year ended 31 December 2023, which is expected to be published by the end of March 2024.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
EuroEyes International Eye Clinic Limited
Dr. Jørn Slot Jørgensen
Chairman and Executive Director

Hong Kong, 5 March 2024

As at the date of this announcement, the Board comprises Dr. Jørn Slot Jørgensen, Dr. Markus Braun, Mr. Jannik Jonas Slot Jørgensen and Professor Dan Zoltan Reinstein as executive Directors; Mr. Marcus Huascar Bracklo as non-executive Director; and Mr. Hans Helmuth Hennig, Ms. Katherine Rong Xin and Mr. Philip Duncan Wright as independent non-executive Directors.